SX-682 (SX682) is a novel boronic acid-containing and selective CXCR2 chemokine receptor antagonist with potential anticancer and immunomodulatory activities.

Reparixin L-lysine salt, the L-lysine salt form of reparixin, is a novel, potent small molecule weight allosteric inhibitor of chemokine receptor 1/2 (CXCR1/2) activation.

MSX127 (NSC23026) is a novel and potent antagonist of CXCR4 receptor with anticancer activity.

ML-339 is a novel and potent hCXCR6 antagonist (IC50 of 140 nM) with anticancer activity and selectivity (IC50 >79 μM) against CXCR5, CXCR4, CCR6 and Apelin receptor (APJ).

Navarixin (formerly known as MK-7123; SCH527123; PS291822) is a novel potent and specific allosteric antagonist of CXCR1 and CXCR2 with antitumor and anti-inflammatory activity and is able to sensitize cells to oxaliplatin in preclinical colon cancer models.